Carvedilol and Terminal state - a phase IV clinical study of FDA data

Summary:

Terminal state is reported as a side effect among people who take Carvedilol (carvedilol), especially for people who are male, 60+ old, also take Sandostatin, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Terminal state when taking Carvedilol. It is created by eHealthMe based on reports of 110,224 people who have side effects when taking Carvedilol from the FDA, and is updated regularly.

What is Carvedilol?

Carvedilol has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 112,649 Carvedilol users. Check the latest studies of Carvedilol.

What is Terminal state?

Terminal state (the transitional states between life and biological death) is found to be associated with 371 drugs and 562 conditions by eHealthMe. Check the latest studies of Terminal state.

On Aug, 12, 2026

110,224 people reported to have side effects when taking Carvedilol.
Among them, 19 people (0.02%) have Terminal state.

Among these 19 people:

What is the gender of people who have Terminal state when taking Carvedilol? *

female: 40 %
male: 60 %

What is the age of people who have Terminal state when taking Carvedilol? *

What are other drugs people take besides Carvedilol? *

What are other side effects people have besides Terminal state? *

Pain: 4 people, 21.05%
Death: 4 people, 21.05%
Fever: 3 people, 15.79%
Fall: 3 people, 15.79%
Oedema Peripheral (superficial swelling): 3 people, 15.79%
Dyspnea (difficult or laboured breathing): 3 people, 15.79%
Urinary Tract Infection: 3 people, 15.79%
General Physical Health Deterioration (weak health status): 3 people, 15.79%
Haematochezia (passage of stools containing blood): 2 people, 10.53%
Head Injury: 2 people, 10.53%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 4 people, 21.05%
Cardiac Disorder: 3 people, 15.79%
Neuroendocrine Tumor: 3 people, 15.79%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 5.26%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 1 person, 5.26%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 5.26%
Cardiac Failure Chronic: 1 person, 5.26%
Chronic Kidney Disease: 1 person, 5.26%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 5.26%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Carvedilol and have Terminal state?

- Check whether Terminal state is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carvedilol:

Carvedilol (112,649 reports)

Terminal state treatments and more:

Terminal state (7,004 reports)

Browse all side effects of Carvedilol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Terminal state:

Terminal state (371 drugs)

Browse all the conditions that are associated with Terminal state:

Terminal state (562 conditions)

Related publications that referenced our studies

Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .
Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on carvedilol (the active ingredients of Carvedilol) and Carvedilol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.